Bristol Myers Squibb Shares Drop Following Mixed Phase 3 Trial Results for Admilparant in IPF
Bristol Myers Squibb (BMY) shares fell approximately 3% on Monday after mixed phase 3 trial results were released for its drug admilparant, which is being tested as a treatment for idiopathic pulmonary fibrosis. The company initially saw higher opening prices but the stock declined following further analysis of the data by investors and analysts. The ALOFT-IPF study did not meet its primary endpoint, raising concerns about the efficacy or safety profile of admilparant in treating this progressive lung disease. Market participants are now reassessing Bristol Myers Squibb's pipeline potential for this drug candidate based on these results. This development has implications for investor confidence and could affect future research funding or partnerships related to IPF therapies.
Tickers: $BMY
Topics: clinical trials drug development idiopathic pulmonary fibrosis (IPF) phase 3 results